With massive social media hype around its intricate world-building and steamy love scenes, perhaps no literary genre has made ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral ...

Bluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Ratio Therapeutics, which specializes in the growing field of radiopharmaceuticals, has inked a deal to build a new research ...

About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct ...

Get ready to rumble. In one corner, it’s President Donald Trump. In the other, it’s the pharmaceutical industry. | President ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Once again, AbbVie dominates doctors’ ranking of makers of immunology meds. | Just like last year, the Skyrizi and Rinvoq ...